Search alternatives:
ng decrease » _ decrease (Expand Search), a decrease (Expand Search), gy decreased (Expand Search)
ns decrease » _ decrease (Expand Search), a decrease (Expand Search), use decreased (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), mean decrease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), mean decrease (Expand Search)
50 ng » 50 mg (Expand Search), 10 ng (Expand Search), 5 ng (Expand Search)
ng decrease » _ decrease (Expand Search), a decrease (Expand Search), gy decreased (Expand Search)
ns decrease » _ decrease (Expand Search), a decrease (Expand Search), use decreased (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), mean decrease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), mean decrease (Expand Search)
50 ng » 50 mg (Expand Search), 10 ng (Expand Search), 5 ng (Expand Search)
-
41
ngLVA degradation kinetics.
Published 2022“…<p>Cos-7 cell infected with L2-euoprom-ngLVA, treated with 34 μg/ml chloramphenicol (CAM) or vehicle only (1:1000 EtOH in RPMI) at 35 hpi (arrow). …”
-
42
-
43
-
44
-
45
-
46
-
47
First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation
Published 2022“…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC<sub>50</sub> value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC<sub>0‑inf</sub> (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …”
-
48
First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation
Published 2022“…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC<sub>50</sub> value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC<sub>0‑inf</sub> (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …”
-
49
-
50
-
51
-
52
-
53
-
54
-
55
-
56
-
57
-
58
-
59
-
60